SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001193125-21-043555
Filing Date
2021-02-16
Accepted
2021-02-16 08:30:59
Documents
2
Group Members
ANSBERT GADICKELUKE EVNINMPM ASSET MANAGEMENT INVESTORS BV2014 LLCMPM ASSET MANAGEMENT LLCMPM BIOVENTURES 2014 (B), L.P.MPM BIOVENTURES 2014 GP LLCMPM BIOVENTURES 2014 LLCMPM ONCOLOGY IMPACT MANAGEMENT GP LLCMPM ONCOLOGY IMPACT MANAGEMENT LPONCOLOGY IMPAC

Document Format Files

Seq Description Document Type Size
1 SC 13D/A d133401dsc13da.htm SC 13D/A 277691
2 EX-99.C d133401dex99c.htm EX-99.C 20390
  Complete submission text file 0001193125-21-043555.txt   300217
Mailing Address C/O MPM ASSET MANAGEMENT LLC 450 KENDALL STREET CAMBRIDGE MA 02142
Business Address C/O MPM ASSET MANAGEMENT LLC 450 KENDALL STREET CAMBRIDGE MA 02142 (617) 425-9200
MPM BioVentures 2014, L.P. (Filed by) CIK: 0001609492 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A

Mailing Address 131 OYSTER POINT BOULEVARD SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 131 OYSTER POINT BOULEVARD SUITE 300 SOUTH SAN FRANCISCO CA 94080 650-443-7400
Harpoon Therapeutics, Inc. (Subject) CIK: 0001708493 (see all company filings)

IRS No.: 473458693 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-90935 | Film No.: 21632827
SIC: 2836 Biological Products, (No Diagnostic Substances)